15,546 Shares in iRadimed Corporation $IRMD Acquired by Globeflex Capital L P

Key Points

• Globeflex Capital acquired 15,546 iRadimed shares worth approximately $1.49 million, while institutional investors collectively own 92.34% of the company.
• iRadimed reported quarterly earnings of $0.46 per share and revenue of $20.47 million, both slightly above analyst expectations. The company maintained 2026 guidance of $2.09–$2.24 in EPS.
• The stock opened at $87.18, below its 50-day and 200-day moving averages, while analysts maintain a “Moderate Buy” consensus with a $120 target price. iRadimed also declared a quarterly dividend of $0.20 per share.

Globeflex Capital L P purchased a new position in shares of iRadimed Corporation (NASDAQ:IRMD - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,546 shares of the medical equipment provider's stock, valued at approximately $1,486,000. Globeflex Capital L P owned about 0.12% of iRadimed as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of IRMD. BlackRock Inc. acquired a new position in iRadimed in the second quarter valued at $92,485,000. Vanguard Group Inc. increased its stake in iRadimed by 1.0% during the third quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider's stock worth $40,313,000 after acquiring an additional 5,475 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its stake in iRadimed by 410.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider's stock worth $24,893,000 after acquiring an additional 205,783 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of iRadimed by 4.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider's stock worth $21,768,000 after purchasing an additional 9,017 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in shares of iRadimed by 37.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider's stock valued at $19,964,000 after purchasing an additional 55,426 shares in the last quarter. Hedge funds and other institutional investors own 92.34% of the company's stock.

Insiders Place Their Bets

In other iRadimed news, CEO Roger E. Susi sold 2,500 shares of the firm's stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $90.60, for a total value of $226,500.00. Following the transaction, the chief executive officer owned 2,162,500 shares of the company's stock, valued at $195,922,500. This trade represents a 0.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 34.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

IRMD has been the subject of several research reports. Wall Street Zen downgraded shares of iRadimed from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Weiss Ratings lowered iRadimed from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, iRadimed has a consensus rating of "Moderate Buy" and a consensus target price of $120.00.

iRadimed Stock Down 0.8%

NASDAQ:IRMD opened at $87.18 on Tuesday. The business's 50 day moving average is $93.31 and its two-hundred day moving average is $94.38. iRadimed Corporation has a 52 week low of $67.84 and a 52 week high of $107.90. The company has a market cap of $1.12 billion, a PE ratio of 48.70 and a beta of 0.90.

iRadimed (NASDAQ:IRMD - Get Free Report) last released its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.02. The firm had revenue of $20.47 million during the quarter, compared to analyst estimates of $20.35 million. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. As a group, sell-side analysts expect that iRadimed Corporation will post 1.98 EPS for the current fiscal year.

iRadimed Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 28th. Investors of record on Friday, August 14th will be given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, August 14th. iRadimed's dividend payout ratio is currently 44.69%.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iRadimed Corporation (NASDAQ:IRMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source